Amgen Inc. (FRA:AMG)
Germany · Delayed Price · Currency is EUR | Market Cap | 150.86B |
| Revenue (ttm) | 30.66B |
| Net Income (ttm) | 5.97B |
| Shares Out | n/a |
| EPS (ttm) | 11.02 |
| PE Ratio | 25.27 |
| Forward PE | 15.63 |
| Dividend | 8.59 (3.10%) |
| Ex-Dividend Date | Aug 22, 2025 |
| Volume | 1,268 |
| Average Volume | 155 |
| Open | 273.50 |
| Previous Close | 273.40 |
| Day's Range | 273.50 - 281.10 |
| 52-Week Range | 230.00 - 307.05 |
| Beta | n/a |
| RSI | 71.63 |
| Earnings Date | Nov 4, 2025 |
About Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.
Financial numbers in USD Financial StatementsNews
Amgen CEO talks trial results of cardiac drug Repatha
Amgen Chairman, President and CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk quarterly results, its recent drug trials, what is ahead for the company and more.
Amgen CEO talks trial results of cardiac drug Repatha
Amgen Chairman, President and CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk quarterly results, its recent drug trials, what is ahead for the company and more.
Amgen CEO Bob Bradway goes one-on-one with Jim Cramer
Amgen Chairman, President and CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk quarterly results, its recent drug trials, what is ahead for the company and more.
CEO of drugmaker Amgen talks new results from cholesterol drug trial
Amgen CEO Bob Bradway told CNBC's Jim Cramer about his company's treatment to reduce heart attack risk.
VIG, AMGN, ETN, UNP: Large Inflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detecte...
Amgen (AMGN) Shares Rise on Positive Study Results for Repatha
Amgen (AMGN) Shares Rise on Positive Study Results for Repatha
Beat the Market the Zacks Way: Amgen, Ciena, Fair Isaac in Focus
Amgen, Ciena, and Fair Isaac shine as Zacks' proven stock-ranking strategies continue to outperform amid market uncertainty.
Amgen (AMGN) Reports Promising Phase 3 Trial Results for Repatha
Amgen (AMGN) Reports Promising Phase 3 Trial Results for Repatha
Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60%
Merck said Saturday its new pill — a potential rival to Regeneron and Amgen — lowered stubbornly high cholesterol by almost 60%.
AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL
Study Also Shows 36% Reduction in Risk of Heart Attack Repatha is the First and Only PCSK9 Inhibitor to Significantly Reduce the Risk of First Heart Attack and Stroke THOUSAND OAKS, Calif. , Nov. 8, ...
Amgen cholesterol drug cuts risk of first cardiac event by 25%
Adding Amgen's cholesterol drug Repatha to standard therapy reduced major cardiovascular events by 25% for at-risk patients who have never had a heart attack or stroke, according to results from a lar...
Amgen: Buy This Cheap Biotech Leader
Stock Of The Day: Will Amgen Reverse Again?
Amgen Inc. (NASDAQ: AMGN) is lower on Thursday. Yesterday, the shares gained almost 8% after the company released earnings . The firm has reached a critical price level. This is why it is our Stock o...
Stock Of The Day: Will Amgen Reverse Again?
Amgen Inc. (NASDAQ:AMGN) is lower on Thursday. Yesterday, the shares gained almost 8% after the company released earnings.
Amgen (AMGN) Receives Neutral Rating with Raised Price Target from Cantor Fitzgerald | AMGN ...
Amgen (AMGN) Receives Neutral Rating with Raised Price Target from Cantor Fitzgerald | AMGN Stock News
AMGN Crosses Above Average Analyst Target
In recent trading, shares of Amgen Inc (Symbol: AMGN) have crossed above the average analyst 12-month target price of $313.92, changing hands for $319.86/share. When a stock reaches the target an anal...
Decoding Amgen Inc (AMGN): A Strategic SWOT Insight
Decoding Amgen Inc (AMGN): A Strategic SWOT Insight
Amgen (AMGN) Shares Cross 3% Yield Mark
Looking at the universe of stocks we cover at Dividend Channel, in trading on Wednesday, shares of Amgen Inc (Symbol: AMGN) were yielding above the 3% mark based on its quarterly dividend (annualized ...
Why Amgen Stock Was Crushing It on Wednesday
Key PointsThe biotech and pharmaceutical mainstay posted its third-quarter results.
Morgan Stanley Adjusts Price Target for Amgen (AMGN) | AMGN Stock News
Morgan Stanley Adjusts Price Target for Amgen (AMGN) | AMGN Stock News
Noteworthy Wednesday Option Activity: XYZ, AMGN, GS
Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Block Inc (Symbol: XYZ), where a total volume of 64,253 contracts has been traded thus ...
Amgen: Q3 Earnings Indicate Strong Emphasis On R&D
Amgen's Q3 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up
AMGN's Q3 earnings and revenues top estimates as key drugs drive double-digit growth. The company also raises its 2025 outlook.
Amgen (AMGN): Wells Fargo Raises Price Target to $300 | AMGN Stock News
Amgen (AMGN): Wells Fargo Raises Price Target to $300 | AMGN Stock News